Go Pro

Andy Hsieh Analyst Performance

Analyst at William Blair

Andy Hsieh is a stock analyst at William Blair in the healthcare sector, covering 16 publicly traded companies. Over the past year, Andy Hsieh has issued 4 stock ratings, including buy and hold recommendations. While full access to Andy Hsieh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andy Hsieh's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
41 Last 8 Years
Buy Recommendations
85.37% 35 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy85.4%35 ratings
Hold14.6%6 ratings
Sell0.0%0 ratings

Out of 41 total stock ratings issued by Andy Hsieh at William Blair, the majority (85.4%) have been Buy recommendations, followed by 14.6% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
87.5% of companies on NASDAQ
14 companies
NYSEAMERICAN
6.3% of companies on NYSEAMERICAN
1 company
NYSE
6.3% of companies on NYSE
1 company

Andy Hsieh, an analyst at William Blair, currently covers 16 companies listed on NASDAQ, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
16 companies
100.0%

Andy Hsieh of William Blair specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
11 companies
68.8%
PHARMACEUTICALS
5 companies
31.3%

Andy Hsieh's Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8/11/2026Downgrade$1.05Market Perform
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
8/3/2026Downgrade$102.32Market Perform
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
12/12/2025Initiated Coverage$15.61Outperform
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
11/3/2025Upgrade$15.38Outperform
Altimmune, Inc. stock logo
ALT
Altimmune
2/28/2025Initiated Coverage$6.42Market Perform
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
2/28/2025Initiated Coverage$7.33Outperform
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2/28/2025Initiated Coverage$2.68Outperform
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2/28/2025Initiated Coverage$22.82Outperform
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2/28/2025Initiated Coverage$3.69Market Perform
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
2/6/2025Initiated Coverage$0.72Outperform